The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.

AstraZeneca has used AI to devise a unique biomarker for its Daiichi Sankyo-partnered Dato-DXd, hoping to differentiate the antibody-drug conjugate from competitors while offering an explanation why the TROP2-directed therapy appears to work only in some non-small cell lung cancer patients.